Evidence map›Paper›PMID 42662619›Full record

ArticleRespiratory medicine case reports2026

A novel homozygous frameshift mutation in exon 13 of SLC34A2 gene causing pulmonary alveolar microlithiasis: A case report.

Mengyu Ge, Shijie Pei, Yongqing Ye, Qiang Shao, Yiting Cheng, Ruiyang Ding

Abstract readCase Reports
In one paragraph

Article in Respiratory medicine case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mengyu GeDepartment of Respiratory and Critical Care Medicine, Lu'an People's Hospital, Lu'an, Anhui, China.
Shijie PeiDepartment of Respiratory and Critical Care Medicine, Lu'an People's Hospital, Lu'an, Anhui, China.
Yongqing YeDepartment of Respiratory and Critical Care Medicine, Lu'an People's Hospital, Lu'an, Anhui, China.
Qiang ShaoDepartment of Respiratory and Critical Care Medicine, Lu'an People's Hospital, Lu'an, Anhui, China.
Yiting ChengDepartment of Respiratory and Critical Care Medicine, Lu'an People's Hospital, Lu'an, Anhui, China.
Ruiyang DingDepartment of Respiratory and Critical Care Medicine, The Affiliated Hospital of Wanxi Health Vocational College, Lu'an, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pulmonary Alveolar Microlithiasis (PAM) is an extremely rare, progressive, and irreversible lung disease characterized by diffuse deposition of calcium phosphate microliths in alveoli. Most cases present with nonspecific symptoms or are asymptomatic, making diagnosis challenging. Methods: We present the case of a 32-year-old male carpenter who was a 15-year smoking and drinking history and admitted due to bilateral lung lesions detected during physical examination, accompanied by intermittent chest tightness, cough and expectoration. Report the clinical manifestations, imaging findings, and analysis of SLC34A2 gene amplification and sequencing results to elucidate the mutation phenotype in this case. Results: Chest CT showed "blizzard-like" diffuse calcified nodules, and genetic testing identified a novel homozygous frameshift deletion mutation c.1903delG (p.C635Afs*34) in exon 13 of the SLC34A2 gene. The diagnosis was highly suggestive of PAM. Conclusion: This case presents a novel pathogenic mutation of SLC34A2 not previously reported, enriching the mutation spectrum of PAM. The high resolution CT combined with genetic testing is emphasized in the diagnosis of PAM.

Indexed as

Case reportGenetic testingHigh-resolution computed tomographyPulmonary alveolar microlithiasisSLC34A2

Identifiers

PMID42662619
PMCPMC13520074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.